azd5148

AZD5148 is an investigational anti-toxin B neutralizing monoclonal antibody developed by AstraZeneca for the prevention and treatment of *Clostridioides difficile* infection (CDI), particularly targeting recurrent cases. Its mechanism of action involves binding to and neutralizing *Clostridium difficile* toxin B (TcdB), a major virulence factor responsible for the pathology of CDI. Preclinical studies have shown that AZD5148 can prevent severe disease in animal models, and it is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers via intravenous or intramuscular administration[3][4][5][7].

Other names

humanised igg1 kappa (YTE) monoclonal antibody against clostridioides difficile toxin bhumanized anti-TcdB monoclonal antibodyanti-toxin B neutralizing monoclonal antibody AZD5148